Albireo Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Albireo Pharma generated cash of -$107,559,000, which is less than the previous year. Cash used in financing activities reached the amount of $2,759,000 last year. Net change in cash is therefore -$3,165,000.
Cash Flow
| 2012 | -16.69M | -59K | 17.10M |
|---|---|---|---|
| 2013 | -18.55M | -118K | 19.40M |
| 2014 | -18.72M | -49K | 3.57M |
| 2015 | -18.20M | 7K | 34.45M |
| 2016 | -8.78M | 25.48M | 7.61M |
| 2017 | -27.56M | 4.31M | 45.83M |
| 2018 | -26.80M | -47K | 139.18M |
| 2019 | -52.91M | -540K | 23.50M |
| 2020 | -101.02M | -78K | 220.27M |
| 2021 | -107.55M | 102.92M | 2.75M |
ALBO Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 251.27M | 131.84M | 163.88M | 53.23M | 29.93M | 5.12M | 24.58M | 39.78M | 39.05M | 38.70M |
Operating activities | ||||||||||
Net income | -34.03M | -107.63M | -62.71M | -46.11M | -24.41M | -16.35M | -18.73M | -14.13M | -19.33M | -20.74M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 274K | 192K | 127K | 45K | 35K | 14K | 197K | 603K | 641K | 725K |
Stock-based compensation expense | 15.93M | 14.61M | 7.57M | 5.54M | 3.7M | 1.13M | 868K | 784K | 1.53M | 1.82M |
| Deferred income tax benefit | 15.93M | 14.61M | 7.57M | 5.54M | 3.7M | 1.13M | 868K | 784K | 1.53M | 1.82M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -3.29M | 0 | 0 | -597K | 28K | 1.24M | 0 | 0 | 0 | 0 |
Inventories | -194K | 0 | 0 | -851K | -2.28M | 3.00M | 0 | 0 | 0 | 0 |
Accounts payable | 1.33M | 275K | 577K | 3.17M | 263K | -1.16M | 249K | -74K | -39K | 63K |
Cash generated by operating activities | -107.55M | -101.02M | -52.91M | -26.80M | -27.56M | -8.78M | -18.20M | -18.72M | -18.55M | -16.69M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -465K | -78K | -540K | -61K | -190K | -3K | 0 | -49K | -118K | -59K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 25.48M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 102.92M | -78K | -540K | -47K | 4.31M | 25.48M | 7K | -49K | -118K | -59K |
Financing activities | ||||||||||
Common Stock Issued | 241K | 193.26M | 20.77M | 94.15M | 48.50M | 40K | 32.14M | 0 | 19.23M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -230K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | -2.15M | 0 | 0 | 0 | 0 |
Cash used in financing activities | 2.75M | 220.27M | 23.50M | 139.18M | 45.83M | 7.61M | 34.45M | 3.57M | 19.40M | 17.10M |
Net Change In Cash | -3.16M | 119.42M | -32.04M | 110.65M | 23.3M | 24.81M | 16.25M | -15.19M | 731K | 349K |
Cash at end of period | 248.10M | 251.27M | 131.84M | 163.88M | 53.23M | 29.93M | 40.84M | 24.58M | 39.78M | 39.05M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |